Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial.

The Lancet Oncology
January 1, 2011
Cited by 1,624

Abstract


Related Papers

No related papers found

Powered by citation graph analysis